1801 - 1825 of 8112 Results
Title
Year
-
RESTRICTEDTitle: Istradefylline for OFF Episodes in Parkinson’s Disease: A US Perspective of Common Clinical ScenariosJournal Name: Degenerative Neurological and Neuromuscular DiseasePublisher: Informa UK LimitedVol: Volume 12Issue #:Start Page: 97End Page: 109Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-ncDOI - Digital Object Identifier: 10.2147/dnnd.s245197Best OA location URL: https://www.dovepress.com/getfile.php?fileID=82354Citation Count: 2
-
OPENTitle: Loss of tau expression attenuates neurodegeneration associated with α-synucleinopathyJournal Name: Translational NeurodegenerationPublisher: Springer Science and Business Media LLCVol: 11Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1186/s40035-022-00309-xBest OA location URL: https://translationalneurodegeneration.biomedcentral.com/counter/pdf/10.1186/s40035-022-00309-xCitation Count: 12
-
RESTRICTEDTitle: LRRK2 as a target for modulating immune system responsesJournal Name: Neurobiology of DiseasePublisher: Elsevier BVVol: 169Issue #:Start Page: 105724End Page: 105724Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.nbd.2022.105724Best OA location URL: https://doi.org/10.1016/j.nbd.2022.105724Citation Count: 14
-
RESTRICTEDTitle: Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's DiseaseJournal Name: DrugsPublisher: Springer Science and Business Media LLCVol: 82Issue #: 10Start Page: 1027End Page: 1053Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1007/s40265-022-01747-7Best OA location URL: https://link.springer.com/content/pdf/10.1007/s40265-022-01747-7.pdfCitation Count: 9
-
RESTRICTEDTitle: Parkinson's Progression Markers Initiative brain autopsy programJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 101Issue #:Start Page: 62End Page: 65Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.06.017Citation Count: 3
-
OPENTitle: Patient Experience in Early-Stage Parkinson’s Disease: Using a Mixed Methods Analysis to Identify Which Concepts Are Cardinal for Clinical Trial Outcome AssessmentJournal Name: Neurology and TherapyPublisher: Springer Science and Business Media LLCVol: 11Issue #: 3Start Page: 1319End Page: 1340Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1007/s40120-022-00375-3Best OA location URL: https://link.springer.com/content/pdf/10.1007/s40120-022-00375-3.pdfCitation Count: 22
-
RESTRICTEDTitle: Reply to: “Diabetes and Neuroaxonal Damage in Parkinson's Disease”Journal Name: Movement DisordersPublisher: WileyVol: 37Issue #: 7Start Page: 1569End Page: 1570Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.29064Citation Count: 0
-
OPENTitle: Synaptic location is a determinant of the detrimental effects of α-synuclein pathology to glutamatergic transmission in the basolateral amygdalaJournal Name: eLifePublisher: eLife Sciences Publications, LtdVol: 11Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.7554/elife.78055Best OA location URL: https://doi.org/10.7554/elife.78055Citation Count: 20
-
RESTRICTEDTitle: The emerging role of LRRK2 in tauopathiesJournal Name: Clinical SciencePublisher: Portland Press Ltd.Vol: 136Issue #: 13Start Page: 1071End Page: 1079Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1042/cs20220067Best OA location URL: https://portlandpress.com/clinsci/article-pdf/136/13/1071/934808/cs-2022-0067.pdfCitation Count: 13
-
OPENTitle: The LRRK2 signaling network converges on a centriolar phospho-Rab10/RILPL1 complex to cause deficits in centrosome cohesion and cell polarizationJournal Name: Biology OpenPublisher: The Company of BiologistsVol: 11Issue #: 8Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1242/bio.059468Best OA location URL: https://doi.org/10.1242/bio.059468Citation Count: 14
-
OPENTitle: Characterization and diagnostic potential of R2* in early-stage progressive supranuclear palsy variantsJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 101Issue #:Start Page: 43End Page: 48Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.06.021Best OA location URL: http://www.prd-journal.com/article/S1353802022002176/pdfCitation Count: 9
-
OPENTitle: Editorial: Digital Innovation and Data-Driven Research in Neurodegenerative DiseasesJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.961847Best OA location URL: https://www.frontiersin.org/articles/10.3389/fneur.2022.961847/pdfCitation Count: 0
-
OPENTitle: Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned ratJournal Name: European Journal of PharmacologyPublisher: Elsevier BVVol: 929Issue #:Start Page: 175090End Page: 175090Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.ejphar.2022.175090Best OA location URL: https://doi.org/10.1016/j.ejphar.2022.175090Citation Count: 9
-
OPENTitle: OnabotulinumtoxinA Dosing, Disease Severity, and Treatment Benefit in Patients With Cervical Dystonia: A Cohort Analysis From CD PROBEJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.914486Best OA location URL: https://www.frontiersin.org/articles/10.3389/fneur.2022.914486/pdfCitation Count: 5
- Targeting NAAA counters dopamine neuron loss and symptom progression in mouse models of parkinsonism2022OPENTitle: Targeting NAAA counters dopamine neuron loss and symptom progression in mouse models of parkinsonismJournal Name: Pharmacological ResearchPublisher: Elsevier BVVol: 182Issue #:Start Page: 106338End Page: 106338Publication Date:Open Access(OA) Status: OPENLicense: publisher-specific-oaDOI - Digital Object Identifier: 10.1016/j.phrs.2022.106338Best OA location URL: http://manuscript.elsevier.com/S1043661822002833/pdf/S1043661822002833.pdfCitation Count: 8
-
RESTRICTEDTitle: A Ranking-based Weakly Supervised Learning model for telemonitoring of Parkinson’s diseaseJournal Name: IISE Transactions on Healthcare Systems EngineeringPublisher: Informa UK LimitedVol: 12Issue #: 4Start Page: 322End Page: 336Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1080/24725579.2022.2091065Citation Count: 2
-
OPENTitle: Geometric framework to predict structure from function in neural networksJournal Name: Physical Review ResearchPublisher: American Physical Society (APS)Vol: 4Issue #: 2Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1103/physrevresearch.4.023255Best OA location URL: http://link.aps.org/pdf/10.1103/PhysRevResearch.4.023255Citation Count: 7
-
RESTRICTEDTitle: Keystroke-Dynamics for Parkinson's Disease Signs Detection in an At-Home Uncontrolled Population: A New Benchmark and MethodJournal Name: IEEE Transactions on Biomedical EngineeringPublisher: Institute of Electrical and Electronics Engineers (IEEE)Vol: 70Issue #: 1Start Page: 182End Page: 192Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1109/tbme.2022.3187309Citation Count: 19
-
OPENTitle: Physical activity and exercise outcomes in Huntington's disease (PACE-HD): results of a 12-month trial-within-cohort feasibility study of a physical activity intervention in people with Huntington's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 101Issue #:Start Page: 75End Page: 89Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.06.013Best OA location URL: http://www.prd-journal.com/article/S1353802022002048/pdfCitation Count: 14
-
RESTRICTEDTitle: A late-onset neurological disorder: is progression inevitable?Journal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 108Issue #:Start Page: 105092End Page: 105092Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.06.014Citation Count: 0
-
OPENTitle: Soluble urokinase-type plasminogen activator receptor (suPAR) is elevated in caregivers of patients with parkinsonismJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 101Issue #:Start Page: 39End Page: 42Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.06.019Citation Count: 0
-
OPENTitle: Telemedicine as an Untapped Opportunity for Parkinson’s Nurses Training in Personalized Care ApproachesJournal Name: Journal of Personalized MedicinePublisher: MDPI AGVol: 12Issue #: 7Start Page: 1057End Page: 1057Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3390/jpm12071057Best OA location URL: https://www.mdpi.com/2075-4426/12/7/1057/pdf?version=1656473097Citation Count: 3
-
OPENTitle: Aromaticity at position 39 in α‐synuclein: A modulator of amyloid fibril assembly and membrane‐bound conformationsJournal Name: Protein SciencePublisher: WileyVol: 31Issue #: 7Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1002/pro.4360Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pro.4360Citation Count: 9
-
RESTRICTEDTitle: Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson DiseaseJournal Name: JAMA NeurologyPublisher: American Medical Association (AMA)Vol: 79Issue #: 7Start Page: 726End Page: 726Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1001/jamaneurol.2022.1601Citation Count: 0
-
RESTRICTEDTitle: Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease—ReplyJournal Name: JAMA NeurologyPublisher: American Medical Association (AMA)Vol: 79Issue #: 7Start Page: 726End Page: 726Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1001/jamaneurol.2022.1604Citation Count: 0